Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 19/20 | 0.70 |
| ▸ | BCL2 | P10415 | 14/20 | 0.55 |
| ▸ | BCL2L2 | Q92843 | 7/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2951512 | 1.00 | BCL2L1 (0.70) | BCL2L1BCL2BCL2L2MCL1DOT1L | |
| SCHEMBL553977 | 1.00 | BCL2L1 (0.70) | BCL2L1BCL2BCL2L2MCL1DOT1L | |
| SCHEMBL2950007 | 0.91 | BCL2L1 (0.63) | BCL2L1BCL2BCL2L2DOT1LALB | |
| SCHEMBL2951517 | 0.87 | BCL2L1 (0.65) | BCL2L1BCL2BCL2L2MCL1DOT1L | |
| SCHEMBL2946725 | 0.87 | BCL2L1 (0.65) | BCL2L1BCL2BCL2L2MCL1DOT1L | |
| SCHEMBL2945668 | 0.85 | BCL2L1 (0.72) | BCL2L1BCL2BCL2L2DOT1LALB | |
| SCHEMBL2952163 | 0.85 | BCL2L1 (0.72) | BCL2L1BCL2BCL2L2DOT1LALB | |
| SCHEMBL1957630 | 0.85 | BCL2L1 (0.72) | BCL2L1BCL2BCL2L2DOT1LALB | |
| SCHEMBL1957631 | 0.85 | BCL2L1 (0.72) | BCL2L1BCL2BCL2L2DOT1LALB | |
| SCHEMBL555322 | 0.85 | BCL2L1 (0.72) | BCL2L1BCL2BCL2L2MCL1ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2882439-B1 | APOPTOSIS-INDUCING AGENTS | ABBVIE INC (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-8883784-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| US-7754886-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-07-13 | — | — | US | disclosed |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | US | disclosed |
| US-7504512-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1318978-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | ABBVIE INC. | 2004-09-30 | — | — | US | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 5/4885BCL2 3/4885BCL2L2 19/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 4/4885BCL2 3/4885BCL2L2 18/4885 |
| US-20040192681-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | BCL2L1 5/4885BCL2 3/4885BCL2L2 19/4885 |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | BCL2L1 2/4885BCL2 1/4885BCL2L2 5/4885 |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BCOR | BCL2L1 6/4885BCL2 2/4885BCL2L2 12/4885 |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | BCL2A1, BCL2, BAX | BCL2L1 5/4885BCL2 2/4885BCL2L2 9/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | BCL2L1 2/4885BCL2 1/4885BCL2L2 5/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | BCL2L1 2/4885BCL2 1/4885BCL2L2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.